Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB3 versus Herceptin in neoadjuvant HER2-positive breast cancer
2013-004172-35Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing SB3 arm with Herceptin arm (2 arms). Primary endpoint: Pathologic complete response rate of the primary breast tumour. Started Dec 2013; status: completed.
02
Drugs
trastuzumabtrastuzumab-dttb
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004172-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004172-35.